| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 7
| Issue : 1 | Page : 2-5 |
|
|
Management of dyslipidemia in chronic kidney disease
Prit Pal Singh, Amresh Krishna, Om Kumar
Department of Nephrology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India
Correspondence Address:
Prit Pal Singh
Room No: 14, Department of Nephrology, Old Administrative Block, Indira Gandhi Institute of Medical Sciences, Sheikhpura, Patna - 800 014, Bihar
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jigims.jigims_6_20
|
|
|
Dyslipidemia is one of the most important modifiable risk factors for cardiovascular morbidity and mortality in chronic kidney disease (CKD) patients. Lipid profile in CKD differs from that in general population. Even at normal or near-normal lipid levels, subparticles are more atherogenic and more pro-inflammatory. Because of altered clearance and metabolism of various lipid-lowering agents in CKD, its safety on long-term use remains a serious concern. Statins and ezetimibe remain drug of choice for most of the patients. The lowest and the safest dose of the drugs is guided by various trials. Until recently, not much study was available to formulate a guideline for these patients. However, recent studies and meta-analysis have solved this problem to some extent and that's evident with latest guidelines published by KDIGO and ACC/AHA.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
